Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_2
1
17%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Other(1)

Detailed Status

Recruiting2
Not yet recruiting1
unknown1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 32 (40.0%)
N/A2 (40.0%)

Trials by Status

not_yet_recruiting117%
recruiting233%
unknown117%
active_not_recruiting117%
completed117%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingnot_applicable

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

NCT06357806
not_yet_recruitingphase_3

Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B

NCT07282249
recruitingnot_applicable

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

NCT06457477
recruiting

A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance

NCT06313255
unknownphase_2

Reducing Proviral HIV DNA With Interferon-a

NCT02227277
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06357806Not Applicable

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Active Not Recruiting
NCT07282249Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B

Not Yet Recruiting
NCT06457477Not Applicable

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Recruiting
NCT06313255

A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance

Recruiting
NCT02227277Phase 2

Reducing Proviral HIV DNA With Interferon-a

Unknown
NCT01718145Phase 3

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6